GlassScriptPhysician profile
Vasant T Temull
NPI 1295256618
$1,865.78
in general payments reported to CMS, 2019-2025
27 companies · $74.69 in 2025
The $74.69 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $195 · 2021: $393 · 2022: $321 · 2023: $509 · 2024: $109 · 2025: $74.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.98 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $330.81 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $218.21 | 2021-2023 | Vraylar |
| Astellas Pharma US INC | $217.65 | 2020-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $151.63 | 2021-2025 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $122.56 | 2019 | |
| Novo Nordisk INC | $121.40 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $112.77 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.83 | 2019-2023 | Lifevest |
| Lilly USA, LLC | $56.48 | 2021-2023 | Mounjaro |
| Mylan Specialty L.P. | $45.81 | 2023-2024 | Yupelri |
| Pfizer INC. | $40.49 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $39.53 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $32.21 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $30.33 | 2023 | Nuzyra |
| Glaxosmithkline, LLC. | $28.66 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.98 | 2024 | Voquezna |
| Viatris Specialty LLC | $22.69 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.18 | 2022 | |
| Amarin Pharma, INC. | $19.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.21 | 2022 | |
| Acadia Pharmaceuticals INC | $16.35 | 2023 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $15.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.28 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.16 | 2022 | |
| Philips North America LLC | $14.94 | 2024 | (Cm9) Amb Mon & Diag Und |
| Supernus Pharmaceuticals, INC. | $13.70 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasant Temull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.